Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD

European Journal of Haematology

Volumn 72, Issue 2, 2004, Pages 145-148

  Wolff, Daniel ^a   Steiner, B ^a   Stilgenbauer, S ^b   Kahl, C ^a   Leithauser M ^a   Junghanss, C ^a   Wilhelm, S ^a   Kleine, H D ^a   Zimmermann, R ^a   Hartung, G ^a   Casper, J ^a   Freund, M ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Campath 1H; CLL; DLI; Docetaxel; GVHD; PBSCT

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BENDAMUSTINE; CANCER ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOCETAXEL; FLUDARABINE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; MITOXANTRONE; MONOCLONAL ANTIBODY; RITUXIMAB; TREOSULFAN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ARTICLE; B CELL LEUKEMIA; CANCER RECURRENCE; CASE REPORT; CHILL; CHRONIC LYMPHATIC LEUKEMIA; DETERIORATION; DRUG EFFICACY; DRUG FEVER; EOSINOPHILIA; GRAFT VERSUS HOST REACTION; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; INFUSION; LEUKOCYTOSIS; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SKIN BIOPSY; SKIN DISEASE; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; RECURRENCE; SKIN DISEASES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 10744230326     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0902-4441.2003.00181.x     Document Type: Article

References (22)

1. DAZZI F, GOLDMAN J. Donor lymphocyte infusions. Curr Opin Hematol 1999;6:394-399.
2. MARKS DI, LUSH R, CAVENAGH J et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002;100:3108-3114.
3. LUZNIK L, FUCHS EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002;9:123-137.
4. PORTER DL, COLLINS RH JR, HARDY C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000;95:1214-1221.
5. GUGLIELMI C, ARCESE W, DAZZI F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002;100:397-405.
6. RAIOLA AM, VAN LINT MT, VALBONESI M et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003;31:687-693.
7. DREGER P, MONTSERRAT E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002;16:985-992.
8. SCHETELIG J, THIEDE C, BORNHAUSER M et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003;21:2747-2753.
9. FUCHS EJ, SEBER A, ALTOMONTE V et al. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions. Bone Marrow Transplant 1998;22:303-305.
10. HALE G, ZHANG MJ, BUNJES D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998;92:4581-4590.
11. KEATING MJ, FLINN I, JAIN V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-3561.
12. KENNEDY B, RAWSTRON A, CARTER C et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99: 2245-2247.
13. DOHNER H, STILGENBAUER S, DOHNER K, BENTZ M, LICHTER P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 1999;77:266-281.
14. REBELLO PR, HALE G, FRIEND PJ, COBBOLD SP, WALDMANN H. Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 1999;68:1417-1420.
15. DOHNER H, STILGENBAUER S, BENNER A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
16. STILGENBAUER S, DOHNER H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002;347:452-453.
17. HAINSWORTH JD, LITCHY S, BARTON JH et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21: 1746-1751.
18. HUHN D, von SCHILLING C, WILHELM M et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326-1331.
19. BUDMAN DR, PETRONI GR, JOHNSON JL et al. Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol 1997;15: 3275-3279.
20. BASARA N, KIEHL MG, FAUSER AA. Eosinophilia indicates the evolution to acute graft-versus-host disease. Blood 2002;100:3055.
21. ELSNER J, HOCHSTETTER R, SPIEKERMANN K, KAPP A. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996;88: 4684-4693.
22. LEE SJ, KLEIN JP, BARRETT AJ et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002;100:406-414.